482656-48-4

Upstream product

• 98-54-4 para-tert-butylphenol 
• 482656-47-3 ethyl (2R)-3-[4-(benzyloxy)phenyl]-2-hydroxypropanoate 
• 141109-83-3 ethyl 3-(4-benzyloxyphenyl)lactate 
• 410079-50-4 (R)-3-(4-benzyloxyphenyl)-2-hydroxypropionitrile 
• 410079-54-8 ethyl (R)-3-(4-hydroxyphenyl)lactate 
• 40167-10-0 2-[4-(benzyloxy)phenyl]acetaldehyde 
• 223127-72-8 ethyl 3-(4-benzyloxyphenyl)-2-(4-tert-butylphenoxy)propionate 
• 62517-34-4 ethyl 2-hydroxy-3-(4-hydroxyphenyl)propionate 
• 100-44-7 benzyl chloride 

Downstream Products

• 710327-30-3 ethyl (S)-2-(4-tert-butylphenoxy)-3-[4-[2-[(4-(pyridin-2-yl)benzoyl)amino]ethoxy]phenyl]propionate 
• 710327-29-0 ethyl (S)-3-[4-(2-tert-butoxycarbonylaminoethoxy)phenyl]-2-(4-tert-butylphenoxy)propionate 
• 482656-49-5 ethyl (S)-2-(4-tert-butylphenoxy)-3-(4-hydroxyphenyl)propionate 

Relevant academic research and scientific papers

NOVEL ANTIDIABETIC COMPOUNDS

The present invention provides novel compounds of the general formula (I), wherein the symbols are same as described in specification, their pharmaceutically acceptable salts, their tautomeric forms, their stereoisomers, pharmaceutical compositions containing them, to process and intermediates for the preparation of the above said compounds, having the utility of these compounds in medicine and to methods for their therapeutic use, and their use in the treatment of diabetes and related diseases.

Synthesis and biological activity of novel α-substituted β-phenylpropionic acids having pyridin-2-ylphenyl moiety as antihyperglycemic agents

We previously reported the identification of novel oximes having 5-benzyl-2,4-thiazolidinedione with antihyperglycemic activity. We now report the synthesis and biological activity of a novel series of oximes and amides having α-substituted-β-phenylpropionic acids. In this series, we obtained potent PPARα/γ dual agonist (S)-9d, with which activation of PPARα and PPARγ was considerably more potent than that of the reference compounds GW9578 22 and rosiglitazone 3, respectively. This means (S)-9d is of the strongest class of PPARα/γ dual agonists. In the course of this study, we also obtained 8h, which indicated potent plasma glucose lowering effect in spite of weak PPARα/γ agonistic activity.

Efficient synthesis of antihyperglycemic (S)-alpha-aryloxy-beta-phenylpropionic acid using a bifunctional asymmetric catalyst.

Antihyperglycemic (S)-alpha-aryloxy-beta-phenylpropionic acid was prepared using catalytic asymmetric cyanosilylation as a key reaction to construct alpha-oxycarboxylic acid moiety.